Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19855627 | 0.93 | PTGS2 (0.33) | FAAHPTGS2FFAR4APP | |
| SCHEMBL19856283 | 0.91 | PTGS2 (0.35) | FAAHPTGS2FFAR4APPPDE2A | |
| SCHEMBL20882742 | 0.90 | PTGS2 (0.34) | FAAHPTGS2FFAR4APPPDE2A | |
| SCHEMBL19854719 | 0.87 | PTGS2 (0.34) | FAAHPTGS2FFAR4 | |
| SCHEMBL21398460 | 0.85 | FAAH (0.31) | FAAHPTGS2PDE2A | |
| SCHEMBL19853926 | 0.83 | S1PR1 (0.33) | OPRL1 | |
| SCHEMBL20882701 | 0.83 | PDE2A (0.33) | PDE2AOPRL1 | |
| SCHEMBL19856349 | 0.83 | FFAR4 (0.32) | FAAHFFAR4APPOPRL1DGAT1 | |
| SCHEMBL21398201 | 0.82 | MEN1 (0.33) | — | |
| SCHEMBL19856353 | 0.81 | TSHR (0.34) | FAAHPTGS2PDE2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20190292463-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2019-09-26 | — | — | US | disclosed |
| EP-3466918-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292463-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, PYM1, MPEG1 | FAAH 3905/4885PTGS2 4466/4885FFAR4 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.